Immix Biopharma Reports $15.9 Million in Q3 Operating Expenses and $340.9 Million in Cash

Immix Biopharma reported a net loss of $13.9 million and operating expenses of $15.9 million for the third quarter of 2026. The company ended September with $340.9 million in cash, cash equivalents and marketable securities, which it expects to fund operations into mid-2028. It also reported an 89…